Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) issued its earnings results on Monday. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.02), MarketWatch Earnings reports. Foghorn Therapeutics had a negative net margin of 566.27% and a negative return on equity of 301.47%. The firm had revenue of $5.31 million […]
Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) had its price objective decreased by research analysts at HC Wainwright from $25.00 to $20.00 in a research report issued on Tuesday, The Fly reports. HC Wainwright’s target price would indicate a potential upside of 268.32% from the company’s previous close. Several other analysts have also recently weighed in […]
Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Rating) have earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among […]
Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) had its price objective reduced by BMO Capital Markets from $20.00 to $19.00 in a research report report published on Tuesday, The Fly reports. A number of other research firms have also recently weighed in on FHTX. Bank of America began coverage on shares of Foghorn Therapeutics in a […]
Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) had its target price reduced by Wedbush from $20.00 to $15.00 in a research note published on Tuesday morning, The Fly reports. Wedbush also issued estimates for Foghorn Therapeutics’ FY2025 earnings at ($1.93) EPS, FY2026 earnings at ($1.94) EPS and FY2027 earnings at $0.84 EPS. FHTX has been the […]